Preliminary Exploration of 18F-FDG PET/CT Metabolic Parameters Combined with Tumor Markers to Predict the Expression of PD-L1 in Gastric Adenocarcinoma
Objective To explore the value of 18F-FDG PET/CT metabolic parameters and clinicopathological features in the expression of Programmed Death Receptor Ligand-1 in patients with gastric adenocarcinoma.Methods Retrospec-tive analysis of clinical data of 100 patients with gastric adenocarcinoma confirmed by tissue biopsy or surgical pathology from December 2016 to August 2023,PET/CT and immunohistochemistry before treatment for all patients,the maximum standard uptake value(SUVmax),tumor metabolic volume(MTV)and total lesion glycolysis(TLG)of primary gastric cancer were measured.PD-L1 CPS ≥ 5 was used as the cut-off value and divided into high expression group and low ex-pression group.All continuous quantitative data were compared between groups by Mann-Whitney U test,all categorical var-iables were compared between groups by Pearson's x2 test,and Logistic regression models were used to screen for independ-ent predictors by univariate and multivariate analyses and to construct models.The diagnostic performance of the model was judged by Receiver operating characteristic(ROC)curve.Results The SUVmax,MTV and TLG of PD-L1 high expres-sion group were higher than those of low expression group(SUVmax:10.50 vs.11.80;MTV:6.30 vs.10.30;TLG:43.30 vs.81.10).Only SUVmax was statistically significant between the groups(P＜0.05).The clinicopathological features of the patients showed that only carbohydrate antigen 125(CA125)was statistically significant between the groups.SUVmax and CA125 were independent predictors.When SUVmax was 11.10 as the cut-off value,the sensitivity of predicting PD-L1 expression in gastric cancer patients was 60.8％,the specificity was 63.3％,and the AUC was 0.620(95％CI:0.510,0.730).After SUVmax combined with CA125,the AUC reached 0.710(95％CI:0.610,0.811).Conclusion SUVmax can predict the expression of PD-L1 in patients with gastric adenocarcinoma,and the predictive efficacy is improved after com-bined with tumor marker CA125.
Gastric adenocarcinoma18F-FDG PET/CTProgrammed Death Receptor Ligand-1Tumor markers
NETL
NSTL
万方数据
